RichardByrdPollardMD

Infectious Disease • Sacramento, CA

Professor, Internal Medicine, UC, Davis School of Medicine

Join to view full profile

Dr. Pollard is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Pollard's full profile

Already have an account?

Office
4150 V St
PSSB G500
Sacramento, CA 95817
Phone+1 916-734-3815

Fax+1 916-734-7766

Education & Training

Emory University School of MedicineResidency, Internal Medicine, 1973 - 1975
Ohio State University HospitalInternship, Internal Medicine, 1970 - 1971
University of Maryland School of MedicineClass of 1970

Certifications & Licensure

CA State Medical License 1975 - 2026
TX State Medical License 1978 - 2002
GA State Medical License 1974 - 1979
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com

Clinical Trials

A Phase II Double-Blind Study of Delavirdine Mesylate ( U-90152 ) in Combination With Zidovudine ( AZT ) and/or Didanosine ( ddI ) Versus AZT and ddI Combination Therapy
Completed
Phase 2
A Study to Evaluate the Effects of Interleukin-12 (rhIL-12) in HIV-Positive Patients With CD4 Cell Counts Less Than 50 Cells/mm3 or 300-500 Cells/mm3
Completed
Phase 1
Treatment With Interleukin-2 (IL-2) Plus Combination Anti-HIV-Drug Therapy (HAART) for Patients Formerly in ACTG 328
Completed
Not Applicable
Comparison of Two Methods in the Treatment of Cytomegalovirus of the Eyes in Patients With AIDS
Completed
Phase 2
The Effectiveness of Three Drug Combinations in HIV-Infected Patients Who Have Taken Zidovudine for More Than 12 Weeks
Completed
Phase 2
The Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Never Used Anti-HIV Drugs
Completed
Phase 2
A Study of HIV-Disease Development in Aging Start of enrollment: 2000 Oct 01
Completed
Phase 2
Effectiveness of Early or Delayed Addition of Hydroxyurea to a Three-Drug Anti-HIV Drug Combination Including Didanosine, in Advanced HIV Patients Who Failed a First or Second Anti-HIV Triple-Drug Therapy
Withdrawn
Phase 2
Interleukin-2 (IL-2) Treatment for HIV Infected Patients Who Have Interrupted Their Anti-HIV Drug Therapy
Completed
Not Applicable
Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation Start of enrollment: 2006 Mar 31
Completed
Phase 1, Phase 2
Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A Start of enrollment: 2006 Sep 01
Completed
Phase 2
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma Start of enrollment: 2007 Nov 01
Completed
Phase 1
Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma Start of enrollment: 2009 Aug 01
Completed
Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma Start of enrollment: 2010 Aug 27
Completed
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

486 citations
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind rando...
Jeffrey L. Lennox, Edwin DeJesus, Adriano Lazzarin, Richard B. Pollard, José Valdez Madruga
Lancet. 2009-09-05
265 citations
Comparison of Sequential Three-Drug Regimens as Initial Therapy for HIV-1 Infection
Gregory K. Robbins, Victor De Gruttola, Robert W. Shafer, Laura M. Smeaton, Sally Snyder
The New England Journal of Medicine. 2003-12-11
207 citations
Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study
David W. Haas, Laura M. Smeaton, Robert W. Shafer, Gregory K. Robbins, Gene D. Morse
The Journal of Infectious Diseases. 2005-12-01

Grant Support

North-Central California-Center For AIDS ResearchNational Center For Research Resources2004–2007
Phase I Study To Evaluate Safety Of Dermavir, A HIV Vaccine, In HIV-I Subjects UNational Center For Research Resources2004
Immune Reconst W Growth Hormone In HIV Inf Subj W/ Incomplete CD4+ Lymphocyte RENational Center For Research Resources2004
HIV-1 Vaccines Designed To Induce Mucosal ImmunityNational Center For Research Resources2004
BAY 50-4798 Administered In Patients W/ HIV Infection On Haart Compared To PatieNational Center For Research Resources2004
Attenuated Strain Of Vaccinia Virus Administered To HIV Inf Indiv W/ ControlledNational Center For Research Resources2004
A Trial To Evaluate The Ability Of IL-2 To Enhance Hiv-Specific Immunity FollowNational Center For Research Resources2004
North-Central California-Center For AIDS ResearchNational Institute Of Allergy And Infectious Diseases2002–2003
Safety, Pharmacokinetics &Effects Of Calanolide On Surrogate MarkersNational Center For Research Resources2000–2002
Pharmacokinetic Study Of Nine Hydroxyurea Regimens In Combination With DDI &D4tNational Center For Research Resources2000–2002
Interactions &Efficacy Of Nevirapine, Abacavir And AmprenavirNational Center For Research Resources2000–2002
Gw433908 Versus Amprenavir In Subjects With HIV-1 InfectionNational Center For Research Resources2000–2002
ACTG 384--Protease Inhibitor &Non-Nucleoside Reverse Transcriptase InhibitorNational Center For Research Resources2000–2002
ACTG 328--Hiv/Immunogenicity Of Remune With Haart Or Haart &Il2National Center For Research Resources2000–2002
Highly Active Antiretroviral Therapy W/Wo Rhil 2 For HIV Positive PatientsNational Center For Research Resources1998–2002
Adult AIDS Clinical Trial UnitNational Institute Of Allergy And Infectious Diseases2000–2001
Clinical Center For Viral Activation Transfusion StudyDivision Of Blood Diseases And Resources1995–2000
Safety Of Recombinant Human Interleukin 12 By Subcutaneous Injection For HIVNational Center For Research Resources1998–1999
Women'S Health AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
Pharmacology AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
Outreach AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
Outcomes Committee AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
Neurology AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
Immunology And Immune Based Therapy AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
HIV Disease Research AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
Core--Advanced Technology LaboratoriesNational Institute Of Allergy And Infectious Diseases1996–1999
Complications Of HIV Disease AgendaNational Institute Of Allergy And Infectious Diseases1996–1999
Adult AIDS Clinical Trials UnitNational Institute Of Allergy And Infectious Diseases1992–1999
Multiple-Dose Safety, PK &Arv Interaction Of Oral Bms-180194 In AIDSNational Center For Research Resources1997
Multiple-Dose Safety, PK &Azt Interaction Of Oral Bms-180194 In AIDSNational Center For Research Resources1996
AIDS Clinical TrialsNational Institute Of Allergy And Infectious Diseases1994–1995
Adult AIDS Clinical ResearchNational Institute Of Allergy And Infectious Diseases1992–1995
Burn Injury Herpesviruses And ImmunityNational Institute Of General Medical Sciences1985–1987

RichardByrdPollardMD

Dr. Pollard is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Grant Support

Viewing the full profile is available to verified healthcare professionals only.